首页> 外文OA文献 >Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series

【2h】

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series

机译：多次每周胰高血糖素的组合治疗如肽-1受体激动剂和二肽肽酶-4型糖尿病患者：案例系列

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Estela Lajthia; John D. Bucheit; Pramit A. Nadpara; Dave L. Dixon; Lauren M. Caldas; Michael Murchie; Evan M. Sisson;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series [J] . Lajthia Estela, Bucheit John D, Nadpara Pramit A, Pharmacy Practice . 2019,第4期

机译：多次每周胰高血糖素的组合治疗如肽-1受体激动剂和二肽肽酶-4型糖尿病患者：案例系列
2. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon- like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes [J] . Nauck Michael A., Kahle Melanie, Baranov Oleg, Diabetes, obesity & metabolism . 2017,第2期

机译：添加二肽肽酶-4抑制剂，SitaGliptin与胰高血糖素样肽-1受体激动剂Liraglutide的持续治疗：2型糖尿病患者的随机对照试验
3. Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes [J] . Amir Hanna . Vincent Woo, Jean-Francois Yale, Elaine M. Cooke, Canadian journal of diabetes . 2012,第1期

机译：基于肠泌素的疗法（胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂）用于治疗2型糖尿病。
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Combinatorial targeting of the glucagon-like peptide-1 and sulfonylurea-1 receptors using a complimentary mulitvalent glucagon-like peptide-1/glibenclamide ligand for the improvement of beta-cell targeting agents and diabetic treatment. [D] . Hart, Nathaniel. 2013

机译：使用互补的多价胰高血糖素样肽-1 /格列苯脲酰胺配体对胰高血糖素样肽-1和磺酰脲-1受体进行联合靶向，以改善β细胞靶向剂和糖尿病治疗。
6. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series [O] . Estela Lajthia, John D. Bucheit, Pramit A. Nadpara, 2019

机译：2型糖尿病每周一次胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的联合治疗
7. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：持续治疗新型抗糖尿病药物（二肽基肽酶-4抑制剂，钠葡萄糖共转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂），其患有2型糖尿病的人：全国范围内的队列研究

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series

著录项

引文网络

相似文献

相关主题

期刊订阅